Roundhill Glp-1 & Weight Loss ETF OZEM
30.65 USD -0.70 (-2.22%)
At closeNov 5, 2026, 4:00 PM EST
30.65 0.00 -0.01%
After hours · Nov 5, 4:00 PM ET
30.65 Day range 31.68
28.34 52-week range 37.15
- YTD
- -10.27%
- 1 year
- +3.91%
- Market cap
- 40.29M
- EPS (ttm)
- 1.60
- P/E ratio
- 19.12
- YTD return
- -10.27%
- 1-year return
- +3.91%
- Volume
- 12.68K
- Avg volume
- 13.96K
- Open
- 31.68
- Previous close
- 31.35
- Day's range
- 30.65 – 31.68
- 52-week range
- 28.34 – 37.15
3M -2.21 (-6.73%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 26.99
- 200-day average
- 27.14
About Roundhill Glp-1 & Weight Loss ETF
The fund's manager will invest at least 80% of its net assets (plus any borrowings for investment purposes) in the equity securities of GLP-1 & Weight Loss Companies or any derivative instruments (such as swap agreements or forward contracts) that utilize one or more GLP-1 & Weight Loss Companies as the reference asset. The fund is non-diversified.
News
Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight Loss 
Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market 
Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) Stock Price Down 0.6% – Time to Sell? 
From Laggard to Leader: The Surprising Comeback of Healthcare 
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win 
Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) Shares Down 0.4% – Time to Sell? 
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage 
Healthcare ETFs: From Broad Exposure to Big Breakthroughs 
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market 
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Your note
Sign in to keep a note on OZEM — it syncs with the Stock Master app.